Morgan Stanley raised the firm’s price target on Johnson & Johnson to $164 from $163 and keeps an Equal Weight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Trump plans to announce ‘major’ tariff on pharmaceutical imports, Reuters says
- Johnson & Johnson assumed at Buy from Neutral at Goldman Sachs
- Johnson & Johnson announces results from Vivacity-MG3 study
- Johnson & Johnson assumed with a Buy at Goldman Sachs
- JNJ, WMT, or AMZN: Which Mega-Cap Stock Is the Best Pick?